Who founded Mogrify Limited?

Mogrify Limited was founded by Julian Gough, Owen Rackham, Jose Polo.

Who are Mogrify Limited's investors?

Mogrify Limited's investors include Ahren Innovation Capital, Astellas Venture Management LLC, Parkwalk Advisors.

Mogrify Limited

4 known investors

Find your way into Mogrify Limited

Paths you didn't know you had: your email and LinkedIn already hold routes to the Mogrify Limited team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another. It targets diseases with high unmet clinical need, initially in otology, ophthalmology, and diabetes.

Biotech Deep Tech Healthtech

Founders & leadership

Julian GoughCo-founderJulian Gough is co-founder of Mogrify, a biotechnology company developing cellular reprogramming therapies. He previously held academic positions with publications in computational methods for molecular and cell biology, and founded other companies including OutSee, focused on genomics analysis for drug discovery.

Owen RackhamCo-founderOwen Rackham is co-founder of Mogrify Limited, a biotechnology company developing in vivo cellular reprogramming therapies. His research background spans computational biology and machine learning applied to large-scale biological datasets, with focus on understanding cellular state transitions and identifying therapeutic interventions grounded in experimental validation.

Jose PoloCo-founder

Darrin M. Disley CEODarrin Disley is CEO of Mogrify Limited and has founded, grown, or invested in over 40 life science and technology companies. He previously co-founded gene editing company Horizon Discovery Group Plc, which he led from seed funding to a £113M IPO on AIM, and has held executive roles at Cardiogeni Plc and Roquefort Therapeutics Plc.

Board

Jane OsbournChair

Investors · 4

Ahren Innovation Capital✓ confirmed by Mogrify LimitedCambridge, Cambridgeshire

How we know: Ahren Innovation Capital's portfolio page · the company's own site · the Companies House PSC register · biospace.com · the VCSheet dataset · Not right? Tell us

Astellas Venture Management LLClisted by Astellas Venture Management LLCSouth San Francisco · $200K – $5M

How we know: a partner's Signal profile · biospace.com · Not right? Tell us

Parkwalk AdvisorsreportedLondon

How we know: a partner's Signal profile · biospace.com · Not right? Tell us

Also in the syndicate · 1

Trend Investment Group

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AOct 2023
Astellas Venture Management (lead), Parkwalk Advisors (lead), Ahren Innovation Capital, Trend Investment Group
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Companies House · registry record

View on Companies House ↗

Registered name: MOGRIFY LIMITED
Company number: 10002103
Status: Active
Company type: Private limited company
Incorporated: 12 Feb 2016
Registered office: 25 Cambridge Science Park, Milton Road, Cambridge, CB4 0FW
Nature of business (SIC): 72110 — Research and experimental development on biotechnology
Previous names: CELL MOGRIFY LIMITED (2016–2019)
Accounts: last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement: last made up to 21 Mar 2026 · next due 4 Apr 2027

Current officers · 4

Joe Caddell — director, appointed 19 Feb 2026
Joe Alan Foster — director, appointed 13 Dec 2022
Julian Gough — director, appointed 12 Feb 2016
Joanna Charlotte Antonia Green — director, appointed 21 Jan 2021

Source: Companies House public register · retrieved 8 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

Mogrify Extends Series A Financing to $46 Million USD - BioSpacebiospace.com · Oct 2023

Frequently asked questions

What does Mogrify Limited do?: Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another. It targets diseases with high unmet clinical need, initially in otology, ophthalmology, and diabetes.
Who founded Mogrify Limited?: Mogrify Limited was founded by Julian Gough, Owen Rackham, Jose Polo.
Who are Mogrify Limited's investors?: Mogrify Limited's investors include Ahren Innovation Capital, Astellas Venture Management LLC, Parkwalk Advisors.